Figure 2. Change in Plasma Levels Following Donanemab Treatment.

Least square (LS) mean change from baseline in plasma phosphorylated tau₂₁₇ (pTAU₂₁₇) (A), glial fibrillary acidic protein (GFAP) (B), neurofilament light chain (NfL) (C), and amyloid-β (Aβ) 42/40 (D) for placebo and donanemab. Plasma values were log₁₀ transformed. Error bars indicate standard error. The dotted line indicates baseline.

^aP < .01 vs placebo.

^bP < .001 vs placebo.

^cP < .05 vs placebo.